By transplanting different subsets of AML cells to immunodeficient NOD/SCID mice, they found that only AML cells within the CD34+CD38− fraction were capable of recapitulating human AML in NOD/SCID recipients; these were referred to as leukemic stem cells (i.e., CSCs for AML). The gene discussed is CD34; the disease is acute myeloid leukemia.